NewGenIvf Group Limited Class A Ordinary Shares (NIVF)vsNovartis AG ADR (NVS)
NIVF
NewGenIvf Group Limited Class A Ordinary Shares
$1.14
-5.00%
HEALTHCARE · Cap: $1.25M
NVS
Novartis AG ADR
$156.08
+3.22%
HEALTHCARE · Cap: $286.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1223921% more annual revenue ($56.69B vs $4.63M). NIVF leads profitability with a 24.2% profit margin vs 22.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NIVF
Avoid34
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NIVF.
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.08
$62.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 79 in profit
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 24 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 4.7%
Operating margin of -184.3%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NIVF
The strongest argument for NIVF centers on Price/Book, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.2% and operating margin at -184.3%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : NIVF
The primary concerns for NIVF are EPS Growth, Market Cap, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NIVF profiles as a declining stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NewGenIvf Group Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
NewGenIvf Group Limited (NIVF) is a pioneering organization in the reproductive health industry, specializing in innovative fertility solutions, including advanced in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive technologies and is strategically positioned to capitalize on the growing global demand for fertility treatments, supported by a robust network of clinics and strategic partnerships. As the fertility services market continues to expand, NIVF is well-equipped for substantial growth, with a mission to assist individuals and couples in their journey to parenthood through forward-thinking healthcare solutions.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?